
    
      1. To evaluate the efficacy of the neoadjuvant combination therapy with letrozole and
           lapatinib in postmenopausal patients with ER-positive and HER2-positive breast cancer.

        2. To assess markers predictive of treatment response and outcome in this setting.
    
  